# US 2012/0083493 A1 · Small-molecule modulators of trp-p8 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083493 A1
- Document ID: US20120083493A1
- Status: Published application
- Kind: A1
- Application number: 12/853,202
- Filed: 2010-08-09
- Published: 2012-04-05
- Earliest claimed: 2006-02-15
- Assignees: Dendreon Corporation
- Inventors: Ofir Moreno; Sateesh Natarajan; David F. Duncan
- Web page: https://patentgrep.com/patent/US20120083493A1

## CPC

- C07C 233/60: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- A61K 31/015: carbocyclic
- A61K 31/095: Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- C07C 233/62: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07C 237/10: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 237/42: having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- C07C 237/44: having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C 323/40: Y being a hydrogen or a carbon atom
- C07C 323/63: the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07D 231/40: Acylated on said nitrogen atom
- C07D 235/26: Oxygen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.

## Claims

### Claim 1

A method for prophylaxis or treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:
wherein R1 is selected from H, alkyl, heteroalkyl, arylalkyl, and aryl, or, R1 and R2 together with the nitrogen group may form a cyclic or heterocyclic group of up to 25 atoms;
R2 is selected from aryl and arylalkyl;
R3 is selected from alkyl, heteroalkyl, and arylalkyl;
R4 is selected from H, alkyl, heteroalkyl, and arylalkyl; and
R3 and R4 together with the nitrogen group form an aliphatic amine;
or a pharmaceutically acceptable salt thereof.

### Claim 2

A method for prophylaxis or treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-A:
wherein A, B, C, and D are independently selected from CR2 and N; wherein at least one of A, B, C, and D is CR2; wherein R2 is a member selected from H, alkyl, heteroalkyl, aryl, halogen, and arylalkyl, R6O—, and R6S—, wherein R6 is alkyl; wherein when two adjacent of A, B, C, and D are C R2, the two R2's may combine to form a single aryl, cycloalkyl, or heterocycloalkyl group; and
R1 is selected from H, alkyl, heteroalkyl, aryl, and arylalkyl;
R3 is selected from alkyl, heteroalkyl, aryl, arylalkyl, —NR7C(O)—, —C(O)NR7—, —O—, —S—, —S(O)—, —S(O)2—, and —NR7—, wherein R7 is a member selected from H, alkyl, heteroalkyl, aryl, and arylalkyl;
R4 is selected from —C(O)R8—, alkyl, arylalkyl, and heteroalkyl, wherein R8 is selected from alkyl and heteroalkyl;
R5 is selected from H, alkyl, heteroalkyl, and arylalkyl; and
R4 and R5 together with the nitrogen group form an aliphatic amine;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method of claim 2 wherein R1 is H.

### Claim 4 (depends on 2)

The method of claim 2 wherein R7 is H.

### Claim 5 (depends on 2)

The method of claim 2 wherein R8 comprises 2, 3, or 4 carbons.

### Claim 6 (depends on 4)

The method of claim 4 wherein R4 is selected from propionyl, ethyl, butyryl, hydroxypropionyl, and 3-hydroxybutyryl.

### Claim 7 (depends on 2)

The method of claim 2 wherein R5 is selected from H and methyl.

### Claim 8 (depends on 2)

The method of claim 2 wherein R6 comprises 1, 2, 3, 4, 5, or 6 carbons.

### Claim 9 (depends on 7)

The method of claim 7 wherein R2 is selected from methoxy, methylsulfanyl, phenyl, and H.

### Claim 10 (depends on 2)

The method of claim 2 wherein said compound comprises a group selected from 2-(2-amino-propionylamino)-4-methoxy-phenyl, N-(2-Amino-ethyl)-2-amino-5-methylsulfanyl-phenyl, 1-(2-amino-ethoxy)-naphthalen-2-yl, 2-(2-amino-ethylamino)-4-methylsulfanyl-phenyl, N-(2-Amino-ethyl)-5-methoxy-benzamide, 2-(2-amino-butyrylamino)-4-methoxy-phenyl, 2-(2-amino-3-hydroxy-propionylamino)-4-methoxy-phenyl, 3-(2-amino-ethylamino)-naphthalen-2-yl, N-(2-Amino-ethyl)-2-amino-benzamide, 2-(2-amino-3-hydroxy-propionylamino)-4-methoxy-phenyl, 2-(2-amino-acetylamino)-phenyl, 2-(2-amino-3-hydroxy-butyrylamino)-4-methoxy-phenylamide, and 2-(2-amino-acetylamino)-4-methoxy-phenyl.

### Claim 11

A method for prophylaxis or treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-B:
wherein R1 is selected from H, alkyl, heteroalkyl, aryl, and arylalkyl;
R2 is selected from aryl, alkyl, heteroalkyl, and arylalkyl;
R3 is selected from alkyl, heteroalkyl, and arylalkyl;
R4 is selected from H, alkyl, heteroalkyl, and arylalkyl; and
R3 and R4 together with the nitrogen group form an aliphatic amine;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

The method of claim 11 wherein R1 is H.

### Claim 13 (depends on 11)

The method of claim 11 wherein R3 comprises 1, 2, 3, 4, 5, or 6 carbons.

### Claim 14 (depends on 13)

The method of claim 13 wherein R3 is selected from methylene, ethylene, propylene, and butylene.

### Claim 15 (depends on 11)

The method of claim 11 wherein R4 is selected from H and methyl.

### Claim 16 (depends on 11)

The method of claim 11 wherein R2 is a group selected from phenyl, furan, methylpyrrole, methylbenzoate, aminophenyl, hydroxyphenyl, cyanophenyl, and methoxyphenyl.

### Claim 17 (depends on 11)

The method of claim 11 wherein said compound comprises a group selected from 2-(2-amino-ethyl)-5-furan-2-yl-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(1-methyl-1H-pyrrol-2-yl)-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(4-amino-phenyl)-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(4-hydroxy-phenyl)-21-1-pyrazol-3-yl, 2-(2-methylamino-ethyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-propyl)-5-phenyl-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(3-cyano-phenyl)-2H-pyrazol-3-yl, 2-(2-amino-ethyl)-5-(3-methoxy-phenyl)-2H-pyrazol-3-yl, 4-{1-(2-Amino-ethyl)-1H-pyrazol-3-yl}-benzoic acid methyl ester, 2-(2-amino-ethyl)-5-(3-amino-phenyl)-2H-pyrazol-3-yl, and 2-(2-amino-ethyl)-5-(3-hydroxy-phenyl)-2H-pyrazol-3-yl.

### Claim 18

A method for prophylaxis or treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-C:
wherein R1 is selected from H, alkyl, heteroalkyl, aryl, and arylalkyl;
R2 is selected from aryl, and arylalkyl;
R3 is selected from alkyl, heteroalkyl, arylalkyl, —NHC(O)R5—, —OR5—, and —NHR5—, wherein R5 is alkyl or heteroalkyl;
R4 is selected from H, alkyl, heteroalkyl, and arylalkyl; and
R3 and R4 together with the nitrogen group form an aliphatic amine;
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18 wherein R1 is H.

### Claim 20 (depends on 18)

The method of claim 18 wherein R2 is phenyl.

### Claim 21 (depends on 18)

The method of claim 18 wherein R5 is selected from, methylene, ethylene, propylene, and butylene.

### Claim 22 (depends on 21)

The method of claim 21 wherein R3 is selected from propionylamino, ethoxy, propoxy, and ethylamino.

### Claim 23 (depends on 18)

The method of claim 18 wherein R4 is selected from H and methyl.

### Claim 24 (depends on 18)

The method of claim 18 wherein said compound comprises a group selected from 2-(2-amino-propionylamino)-2-phenyl-ethyl, 2-(2-amino-ethoxy)-2-phenyl-ethyl, 2-(2-amino-ethoxy)-2-phenyl-ethyl, 2-(3-amino-propoxy)-2-phenyl-ethyl, 2-(2-dimethylamino-ethoxy)-2-phenyl-ethyl, and 2-(2-amino-ethylamino)-2-phenyl-ethyl.

### Claim 25

A method for prophylaxis or treatment of benign prostatic hyperplasia (BPH), an enlarged prostate, acute urinary retention, or symptoms thereof or reducing prostate size in a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I-D:
wherein R1 is selected from H, alkyl, heteroalkyl, aryl, and arylalkyl;
R2 is selected from aryl, and arylalkyl;
R3 is selected from alkyl, heteroalkyl, and arylalkyl;
R4 is selected from H, alkyl, heteroalkyl, and arylalkyl; and
R3 and R4 together with the nitrogen group form an aliphatic amine;
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The method of claim 25 wherein R1 is H.

### Claim 27 (depends on 25)

The method of claim 25 wherein R2 is selected from phenyl and phenylamino.

### Claim 28 (depends on 25)

The method of claim 25 wherein R3 is selected from methylene, ethylene, propylene, butylene, methylamino, ethylamino, propylamino, butylamino, and acetyl.

### Claim 29 (depends on 25)

The method of claim 25 wherein R4 is selected from H and methyl.

### Claim 30 (depends on 25)

The method of claim 25 wherein said compound comprises a group selected from 2-[2-(2-amino-ethylamino)-phenyl]-ethyl, 2-(2-aminomethyl-phenyl)-ethyl, and 2-[(2-amino-acetyl)-phenyl-amino]-ethyl.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46 (depends on 1)

A method of claim 1, said method further comprising administration of one or more benign prostatic hyperplasia (BPH) therapeutic agents.

### Claim 47 (depends on 47)

The method of claim 47 wherein said combination is administered simultaneously.

### Claim 48 (depends on 47)

The method of claim 47 wherein said mammal is a human.

### Claim 49

A method comprising (a) advertising the use of a compound of Formula I, a compound of Formula I-A, a compound of Formula I-B, a compound of Formula I-C, a compound of Formula I-D, and combinations thereof, or a pharmaceutically acceptable salt thereof; for treatment of BPH, and (b) selling said compound to individuals for use for treatment of BPH.

### Claim 50

The use of a compound selected from the group consisting of a compound of Formula I, a compound of Formula I-A, a compound of Formula I-B, a compound of Formula I-C, a compound of Formula I-D, and combinations thereof, or a pharmaceutically acceptable salt thereof, to prepare a medicament useful for treating or preventing benign prostatic hyperplasia (BPH).
